Avanos Medical, Inc. (AVNS)
- Previous Close
18.76 - Open
18.61 - Bid 7.49 x 800
- Ask 18.68 x 800
- Day's Range
18.55 - 18.83 - 52 Week Range
17.24 - 30.28 - Volume
157,349 - Avg. Volume
248,651 - Market Cap (intraday)
864.479M - Beta (5Y Monthly) 0.96
- PE Ratio (TTM)
-- - EPS (TTM)
-0.21 - Earnings Date May 1, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
23.50
Avanos Medical, Inc., a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides a portfolio of non-opioid pain solutions, including surgical pain and recovery products, such as ON-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy; OrthogenRx's knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
avanos.comRecent News: AVNS
Performance Overview: AVNS
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AVNS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AVNS
Valuation Measures
Market Cap
864.48M
Enterprise Value
985.88M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.29
Price/Book (mrq)
0.70
Enterprise Value/Revenue
1.46
Enterprise Value/EBITDA
18.53
Financial Highlights
Profitability and Income Statement
Profit Margin
-9.18%
Return on Assets (ttm)
1.64%
Return on Equity (ttm)
-0.78%
Revenue (ttm)
673.3M
Net Income Avi to Common (ttm)
-9.9M
Diluted EPS (ttm)
-0.21
Balance Sheet and Cash Flow
Total Cash (mrq)
87.7M
Total Debt/Equity (mrq)
16.91%
Levered Free Cash Flow (ttm)
200.79M
Research Analysis: AVNS
Company Insights: AVNS
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: AVNS
AVNS: Lowering target price to $25.00
AVANOS MEDICAL INC has an Investment Rating of HOLD; a target price of $25.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetAVNS: Lowering target price to $26.00
AVANOS MEDICAL INC has an Investment Rating of HOLD; a target price of $26.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetAVNS: What does Argus have to say about AVNS?
AVANOS MEDICAL INC has an Investment Rating of HOLD; a target price of $27.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetAVNS: Raising target price to $27.00
AVANOS MEDICAL INC has an Investment Rating of HOLD; a target price of $27.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice Target